TABLE 1.
FSGS donor and organ characteristics are described for SA or SF, SSO, and SWO subjects
| FSGS donor/organ characteristics | SA (n = 2395) | SF (n = 913) | SSO (n = 295) | SWO (n = 519) | All group comparison P * |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | ||
| Living donor, n (%) | 763 (31.9%) | 427 (46.8%) | 111 (37.6%) | 169 (32.6%) | <0.001a,c,d |
| Related living donor, n (%) | 340 (44.6%) | 196 (45.9%) | 53 (47.7%) | 78 (46.2%) | 0.908 |
| Deceased donor cardiovascular COD, n (%) | 259 (15.9%) | 74 (15.2%) | 28 (15.2%) | 54 (15.4%) | 0.983 |
| ECD donor or not, n (%) | 155 (9.5%) | 48 (9.9%) | 19 (10.3%) | 51 (14.6%) | 0.043b |
| Gender (male), n (%) | 1373 (57.3%) | 487 (53.3%) | 154 (52.2%) | 283 (54.5%) | 0.094 |
| Ethnicity, n (%) | 0.095 | ||||
| White | 1587 (66.3%) | 626 (68.6%) | 201 (68.1%) | 369 (71.1%) | |
| Black | 375 (15.7%) | 124 (13.6%) | 40 (13.6%) | 72 (13.9%) | |
| Hispanic | 314 (13.1%) | 131 (14.4%) | 35 (11.9%) | 63 (12.1%) | |
| Other | 119 (5%) | 32 (3.5%) | 19 (6.4%) | 15 (2.9%) | |
| HLA-DR mismatch, n (%) | 0.107 | ||||
| 0 | 319 (13.4%) | 142 (15.6%) | 38 (12.9%) | 72 (13.9%) | |
| 1 | 1217 (51%) | 482 (53.1%) | 167 (56.6%) | 258 (49.7%) | |
| 2 | 852 (35.7%) | 284 (31.3%) | 90 (30.5%) | 187 (36%) | |
| HLA-A mismatch, n (%) | 0.101 | ||||
| 0 | 297 (12.4%) | 128 (14.1%) | 29 (9.8%) | 77 (14.8%) | |
| 1 | 1023 (42.8%) | 416 (45.8%) | 132 (44.7%) | 214 (41.2%) | |
| 2 | 1068 (44.7%) | 364 (40.1%) | 134 (45.4%) | 226 (43.5%) | |
| HLA-B mismatch, n (%) | 0.413 | ||||
| 0 | 177 (7.4%) | 82 (9%) | 19 (6.4%) | 37 (7.1%) | |
| 1 | 734 (30.7%) | 300 (33%) | 96 (32.5%) | 162 (31.2%) | |
| 2 | 1477 (61.9%) | 526 (57.9%) | 180 (61%) | 318 (61.3%) | |
| HLA mismatch, median, IQR/n (%) | 4 (3–5%) | 4 (3–5%) | 4 (3–5%) | 4 (3–5%) | 0.018a |
| 0 | 101 (4.2%) | 42 (4.6%) | 7 (2.4%) | 25 (4.8%) | |
| 1 | 30 (1.3%) | 23 (2.5%) | 7 (2.4%) | 14 (2.7%) | |
| 2 | 162 (6.8%) | 93 (10.2%) | 21 (7.1%) | 33 (6.4%) | |
| 3 | 425 (17.8%) | 153 (16.9%) | 59 (20%) | 85 (16.4%) | |
| 4 | 575 (24.1%) | 220 (24.2%) | 66 (22.4%) | 120 (23.1%) | |
| 5 | 731 (30.6%) | 264 (29.1%) | 97 (32.9%) | 159 (30.6%) | |
| 6 | 364 (15.2%) | 113 (12.4%) | 38 (12.9%) | 81 (15.6%) | |
| KDPI, mean (SD) | 0.4 (0.3) | 0.4 (0.3) | 0.5 (0.3) | 0.4 (0.3) | 0.073 |
| Age, mean (SD) | 37 (14.5) | 37.2 (14.3) | 38.4 (14.9) | 38.9 (14.8) | 0.026b |
| Cold ischemic time, median (IQR) | 12 (2.9–19.96) | 8.97 (1–19) | 10.56 (1.7–20.39) | 10.81 (2–18.01) | <0.001a |
Groups were compared by chi-square tests, 1-way ANOVA, or Kruskal-Wallis tests, and 2-tailed P values are shown. Post hoc comparisons were adjusted using Holm methods.
*Superscript indicates which pairwise comparisons are significant.
aSignificant post hoc pairwise comparison between SA and SF.
bSignificant post hoc pairwise comparison between SA and SWO.
cSignificant post hoc pairwise comparison between SF and SSO.
dSignificant post hoc pairwise comparison between SF and SWO.
eSignificant post hoc pairwise comparison between SSO and SWO.
COD, cause of death; ECD, extended criteria donor; FSGS, focal segmental glomerulosclerosis; IQR, interquartile range; KDPI, Kidney Donor Profile Index; SA, steroid always; SF, steroid free; SSO, steroid switch on; SWO, steroid wean off.